Sex Differences in Neuropeptide Y Serum, But Not in Fat Intake and Body Mass Index

What Was Tested

This registered not phased trial tested Neuropeptide Y.

One's appetite has a role in controlling food intake and maintaining energy balance, but its effect on body metabolism related to obesity is still questionable.

The purpose of this study was to determine the levels of neuropeptide Y in healthy people and to see differences in gender and anthropometric parameters.

The hypothesis of this study was that there would be differences in neuropeptide Y levels in groups with gender and anthropometric parameter differences.

It had two arms (groups): Healthy group (active comparator) and Non-healthy group (active comparator).

Healthy men and women aged 20-60 years old.

Pregnant women, nursing mothers, impaired kidney and liver function, chronic disease, or other metabolic disorders.

The registry classes the interventions as diagnostic test.

More on the Plan

This study was a cross-sectional study involving 62 study subjects, male and female, who did not have chronic diseases or metabolic disorders.

This research was conducted from April to September 2020.

The parameters examined in this study were neuropeptide Y levels and anthropometric parameters.

The statistical analysis performed was the Mann-Whitney test to see the differences between groups.

Who Took Part

Enrollment: 62 actual participants took part.

It was open to people of any sex aged from 20 years up to 60 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Healthy groups for Neuropeptide Y Serum diagnosis.

The full record lists 1 inclusion and 1 exclusion criteria; among the exclusions: non-healthy groups for neuropeptide y serum diagnosis.

How the Study Was Run

The set-up was randomized, parallel-group and single-blind.

The participants were allocated by chance, so the Neuropeptide Y group and the comparison group should start out alike.

Groups ran in parallel: each of the participants stayed in one arm throughout.

In this single-blind Neuropeptide Y study one party knew the assignments and the other did not.

Those kept unaware of assignments: participant.

It started in 2020-04-02 with completion listed for 2020-06-17.

It ran at 1 site in Indonesia.

Its stated primary purpose is diagnostic.

What Was Measured

Primary outcome: levels of neuropeptide Y (time frame: up to 2 weeks).

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of Neuropeptide Y in 62 people.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Neuropeptide Y compound page, all human trials.